

Immunolight Selected to Present at 2024 Future in Review Conference

The recognition highlights our groundbreaking contributions to the field of medicine, particularly our advancements with Immunolight Cancer Therapy.



DURHAM, NORTH CAROLINA, UNITED STATES, July 16, 2024 /EINPresswire.com/ --

[Immunolight](#) is excited to announce that we have been selected as one of twelve start-up companies featured at the 2024 Future in Review Conference (FiRe) in Palos Verdes, California.

“

For years the Future in Review Conference has showcased events and trends that will dramatically impact the world as we know it today.”

*Harold Walder, President,
Immunolight*

This prestigious recognition highlights our groundbreaking contributions to the field of medicine, particularly our revolutionary advancements with Immunolight Cancer Therapy (ICT), our experimental, non-chemotherapy cancer treatment for solid tumors. This novel, innovative technology has the potential to transform the landscape of cancer treatment, offering new hope and improved outcomes for patients worldwide. We are also excited to share how our technology can innovate commercial and industrial uses of adhesives, solar and the generation of color.

The Future in Review Conference is renowned for bringing together the most forward-thinking leaders in science and technology. As a featured presenter, Immunolight will have the opportunity to showcase our latest advancements and engage with top experts and thought leaders in various industries. We’re eager to share our progress, exchange ideas, and explore potential collaborations across the medical and commercial landscape.

“For years the Future in Review Conference has showcased events and trends that will dramatically impact the world as we know it today,” said Immunolight President Harold Walder. “We are honored to be selected to participate with this elite group and excited to showcase what we hope will be a paradigm shift in the treatment of cancer.”

The 2024 Future in Review Conference will take place from October 20-23 at the Terranea Resort in Palos Verdes, California.

About Immunolight, LLC

Founded in 2007, Immunolight, LLC's mission is to innovate advancements in energy conversion technologies that create value in medicine, commercial industries, and the life sciences. Immunolight has developed a breakthrough platform technology that leverages the latest advances in energy conversion. The technology is centered on energy conversion from one part of the electromagnetic spectrum to another and the paradigm-shifting applications in a variety of medical and non-medical commercial fields. Immunolight's highest priority is to translate innovations in energy conversion, the company's core technology, to fulfill a high, unmet medical need in the development of new possibilities for targeted therapies to treat cancer, particularly through its [Immunolight Cancer Treatment](#) (formerly X-PACT).

Contact: Harold Walder, President of Immunolight at hwalder@immunolight.com.

Harold Walder

Immunolight

hwalder@immunolight.com

Visit us on social media:

[Facebook](#)

[LinkedIn](#)

[Instagram](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/728091620>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.